Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$5.32 USD
+0.05 (0.95%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $5.32 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VNDA 5.32 +0.05(0.95%)
Will VNDA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VNDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VNDA
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
VNDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
Other News for VNDA
Vanda Pharmaceuticals drops after Future Pak walks away
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Accenture, KB Home rise; Snap, Jabil fall, Thursday, 6/20/2024
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Vanda slips after rejecting takeover offers